Igene Biotechnology, Inc.
IGNE · OTC
12/31/2009 | 12/31/2008 | 12/31/2007 | 12/31/2006 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.10 | -0.01 | -0.01 | 0.00 |
| FCF Yield | -1.75% | 42.72% | 72.62% | 0.00% |
| EV / EBITDA | -24.53 | -2.40 | 60.79 | -62.59 |
| Quality | ||||
| ROIC | -120.23% | -130.53% | -29.84% | 710.23% |
| Gross Margin | 25.66% | 16.34% | 26.46% | 0.00% |
| Cash Conversion Ratio | 0.69 | -0.18 | -0.69 | -0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 20.07% | – | 70.24% | -100.00% |
| Free Cash Flow Growth | -156.07% | -53.69% | 1,035,285.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -6.46 | -1.86 | 56.39 | -52.02 |
| Interest Coverage | -10.97 | -1.08 | 0.11 | -0.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 2.67 | 0.21 | 0.00 |
| Cash Conversion Cycle | -73.85 | 127.14 | 1,593.23 | 0.00 |